Skip to main content
Top
Published in: Medical Oncology 8/2014

01-08-2014 | Short Communication

Analysis of V600E BRAF and D816V KIT mutations in systemic mastocytosis

Authors: H. Hägglund, B. Sander, A. Ahmadi, T. Gülen, G. Nilsson

Published in: Medical Oncology | Issue 8/2014

Login to get access

Abstract

Most patients with systemic mastocytosis (SM) carry a D816 V KIT mutation causing a ligand-independent activation of the receptor. Down-stream of KIT is several components known to be mutated in different malignancies. RAF is among the most frequently mutated kinases, where BRAF V600E mutation occurs in most hairy cell leukemias (HCL) and half of malignant melanomas. We investigated BRAF mutations in 36 subjects with different forms of SM, but could not detect BRAF mutation in any of the cases, not even in the mast cell lineage of a patient with V600E BRAF-positive HCL. Thus, although BRAF is commonly mutated it appears not to be present in SM.
Literature
2.
go back to reference Valent P, Akin C, Escribano L, et al. Standards and standardization in mastocytosis: consensus statements on diagnostics, treatment recommendations and response criteria. Eur J Clin Invest. 2007;37:435–53.PubMedCrossRef Valent P, Akin C, Escribano L, et al. Standards and standardization in mastocytosis: consensus statements on diagnostics, treatment recommendations and response criteria. Eur J Clin Invest. 2007;37:435–53.PubMedCrossRef
3.
go back to reference Valent P, Sperr WR, Akin C. How I treat patients with advanced systemic mastocytosis. Blood. 2010;116:5812–7.PubMedCrossRef Valent P, Sperr WR, Akin C. How I treat patients with advanced systemic mastocytosis. Blood. 2010;116:5812–7.PubMedCrossRef
4.
go back to reference Gotlib J, Kluin-Nelemans H, George T, et al. Durabel responses and improved quality of life with midostaurin (PKC412) in advanced systemic mastocytosis (SM): Updated stage 1 results of the global D2201 trial. Abstract 106, 55th American Society of Hemtology meeting. 2013. Gotlib J, Kluin-Nelemans H, George T, et al. Durabel responses and improved quality of life with midostaurin (PKC412) in advanced systemic mastocytosis (SM): Updated stage 1 results of the global D2201 trial. Abstract 106, 55th American Society of Hemtology meeting. 2013.
5.
go back to reference Schwaab J, Schnittger S, Sotlar K, et al. Comprehensive mutational profiling in advanced systemic mastocytosis. Blood. 2013;122:2460–6.PubMedCrossRef Schwaab J, Schnittger S, Sotlar K, et al. Comprehensive mutational profiling in advanced systemic mastocytosis. Blood. 2013;122:2460–6.PubMedCrossRef
6.
go back to reference Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature. 2002;417:949–54.PubMedCrossRef Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature. 2002;417:949–54.PubMedCrossRef
8.
go back to reference Curtin JA, Fridlyand J, Kageshita T, et al. Distinct sets of genetic alterations in melanoma. N Engl J Med. 2005;353:2135–47.PubMedCrossRef Curtin JA, Fridlyand J, Kageshita T, et al. Distinct sets of genetic alterations in melanoma. N Engl J Med. 2005;353:2135–47.PubMedCrossRef
9.
go back to reference Pardanani A, Tefferi A. BRAF mutations in hairy-cell leukemia. N Engl J Med. 2011;365: 961; author reply -2. Pardanani A, Tefferi A. BRAF mutations in hairy-cell leukemia. N Engl J Med. 2011;365: 961; author reply -2.
10.
go back to reference Gülen T, Sander B, Nilsson G, Palmblad J, Sotlar K, Horny HP, Hagglund H. Systemic mastocytosis: progressive evolution of an occult disease into fatal mast cell leukemia: unique findings on an unusual hematological neoplasm. Med Oncol. 2012;29:3540–6.PubMedCrossRef Gülen T, Sander B, Nilsson G, Palmblad J, Sotlar K, Horny HP, Hagglund H. Systemic mastocytosis: progressive evolution of an occult disease into fatal mast cell leukemia: unique findings on an unusual hematological neoplasm. Med Oncol. 2012;29:3540–6.PubMedCrossRef
11.
go back to reference Hägglund H, Sander B, Gülen T, Lindelof B, Nilsson G. Increased risk of malignant melanoma in patients with systemic mastocytosis? Acta Derm Venereol. 2014; doi:10.2340/00015555-1788. Hägglund H, Sander B, Gülen T, Lindelof B, Nilsson G. Increased risk of malignant melanoma in patients with systemic mastocytosis? Acta Derm Venereol. 2014; doi:10.​2340/​00015555-1788.
12.
go back to reference Sotlar K, Escribano L, Landt O, et al. One-step detection of c-kit point mutations using peptide nucleic acid-mediated polymerase chain reaction clamping and hybridization probes. Am J Pathol. 2003;162:737–46.PubMedCentralPubMedCrossRef Sotlar K, Escribano L, Landt O, et al. One-step detection of c-kit point mutations using peptide nucleic acid-mediated polymerase chain reaction clamping and hybridization probes. Am J Pathol. 2003;162:737–46.PubMedCentralPubMedCrossRef
Metadata
Title
Analysis of V600E BRAF and D816V KIT mutations in systemic mastocytosis
Authors
H. Hägglund
B. Sander
A. Ahmadi
T. Gülen
G. Nilsson
Publication date
01-08-2014
Publisher
Springer US
Published in
Medical Oncology / Issue 8/2014
Print ISSN: 1357-0560
Electronic ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-014-0123-4

Other articles of this Issue 8/2014

Medical Oncology 8/2014 Go to the issue